First patient dosed in Merck’s Phase III PROCEADE-CRC-03 trial for mCRC

​Merck KGaA has dosed the first patient in its Phase III PROCEADE-CRC-03 trial, assessing the investigational anti-CEACAM5 ADC precemtabart tocentecan for mCRC.

The post First patient dosed in Merck’s Phase III PROCEADE-CRC-03 trial for mCRC appeared first on Hospital Management.

 

Back to the Featured Stories

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.